AbbVie (ABBV) Non-Current Assets (2012 - 2026)
AbbVie (ABBV) posted quarterly Non-Current Assets of $102.9 billion for Q1 2026, down 5.12% year-over-year from $108.5 billion in Q1 2025, and down 1.87% quarter-over-quarter from $104.9 billion in Q4 2025.
AbbVie (ABBV) Non-Current Assets (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Non-Current Assets for 15 consecutive years, with $102.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 5.12% year-over-year to $102.9 billion; the TTM figure through Mar 2026 stood at $421.1 billion (down 4.69% YoY), while the FY2025 annual figure was $104.9 billion, down 4.27% from the prior year.
- Non-Current Assets slipped to $102.9 billion in Q1 2026 per ABBV's latest filing, from $104.9 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $116.7 billion in Q1 2022 and bottomed at $101.7 billion in Q4 2023.
- Historically, Non-Current Assets has averaged $108.5 billion across 5 years, with a median of $108.1 billion in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Assets grew 12.27% — and 2025, when it decreased 8.89%.
- AbbVie's Non-Current Assets stood at $110.3 billion in 2022, then fell by 7.82% to $101.7 billion in 2023, then climbed by 7.74% to $109.6 billion in 2024, then slipped by 4.27% to $104.9 billion in 2025, then declined by 1.87% to $102.9 billion in 2026.
- Business Quant data shows ABBV's Non-Current Assets at $102.9 billion in Q1 2026, $104.9 billion in Q4 2025, and $105.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 113.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 101.45 Bn |
| Mar 31, 2026 | 102.93 Bn |
| Dec 31, 2025 | 104.90 Bn |
| Sep 30, 2025 | 105.36 Bn |
| Jun 30, 2025 | 107.92 Bn |
| Mar 31, 2025 | 108.49 Bn |
| Dec 31, 2024 | 109.58 Bn |
| Sep 30, 2024 | 115.64 Bn |
| Jun 30, 2024 | 108.12 Bn |
| Mar 31, 2024 | 110.00 Bn |
| Dec 31, 2023 | 101.71 Bn |
| Sep 30, 2023 | 103.00 Bn |
| Jun 30, 2023 | 106.52 Bn |
| Mar 31, 2023 | 108.06 Bn |
| Dec 31, 2022 | 110.34 Bn |
| Sep 30, 2022 | 110.96 Bn |
| Jun 30, 2022 | 114.09 Bn |
| Mar 31, 2022 | 116.70 Bn |
| Dec 31, 2021 | 118.60 Bn |
| Sep 30, 2021 | 119.90 Bn |